First Allied Advisory Services’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

First Allied Advisory Services’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-358	Closed	–	–	1704
2019 Q3	$0	Buy	+358	New	+$193	﹤0.01%	1700
2018 Q1	–	Sell	-1,253	Closed	–	–	1592
2017 Q4	$0	Buy	+1,253	New	+$475	﹤0.01%	1587

Other funds holding GCVRZ

Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return

New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Michael F. Price $846M AUM 0.07% 1-Year Est. Return

First Allied Advisory Services's GCVRZ Position: Q4 2019 in Review

First Allied Advisory Services sold out of Sanofi Contingent Value Rights (GCVRZ) in Q4 2019, closing a stake of 358 shares.

First Allied Advisory Services first reported a position in GCVRZ in Q4 2017 and held it in 2 quarters. The position peaked at $0 in Q3 2019. 103 funds tracked by Wall St. Rank hold GCVRZ as of Q4 2019.

First Allied Advisory Services reported no remaining Sanofi Contingent Value Rights position as of Q4 2019 after selling out during the quarter.
First Allied Advisory Services sold 358 Sanofi Contingent Value Rights shares in Q4 2019.
First Allied Advisory Services first reported a position in Sanofi Contingent Value Rights in Q4 2017 and held it in 2 quarters.
First Allied Advisory Services's Sanofi Contingent Value Rights position peaked at $0 in Q3 2019.
103 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q4 2019.

Based on First Allied Advisory Services's 13F filing for Q4 2019, filed 10 Feb 2020.